Ignite Creation Date:
2024-05-06 @ 5:46 PM
Last Modification Date:
2024-10-26 @ 2:35 PM
Study NCT ID:
NCT05424380
Status:
TERMINATED
Last Update Posted:
2024-01-26
First Post:
2022-06-15
Brief Title:
A Phase 1 Open Label Study of Intravenous GSK3745417 to Evaluate Safety Tolerability Pharmacokinetics Pharmacodynamics and Determine RP2D Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
Sponsor:
Organization:
GlaxoSmithKline